DNA flow cytometry as a surrogate end-point in patients with superficial bladder cancer treated with 4-HPR.
Decensi
A
A
Department of Medical Oncology II, National Institute for Cancer Research, Genoa, Italy.
Curotto
A
A
Bruno
S
S
Costantini
M
M
Torrisi
R
R
Gatteschi
B
B
Cussotto
M
M
Pizzorno
R
R
Quattrini
S
S
Repetto
U
U
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000782:Aneuploidy; D004273:DNA, Neoplasm / Q000032:analysis*; D004171:Diploidy; D005240:Feasibility Studies; D005260:Female; D017313:Fenretinide / Q000009:adverse effects / Q000627:therapeutic use*; D005434:Flow Cytometry; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010865:Pilot Projects; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*
D004273:DNA, Neoplasm; D017313:Fenretinide